ProQR®

DEVELOPING RNA-EDITING MEDICINES

for patients in need

Nasdaq: PRQR

Date: September 2023

Forward-looking statements

This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our strategy and future operations, statements regarding the potential of and our plans with respect to our technologies and platforms (including Axiomer®), our preclinical model data, our pipeline targets, our other programs and business operations, our current and planned partnerships and collaborators and the intended benefits thereof, including the collaboration with Lilly and the intended benefits thereof, including the upfront payment, equity investment, and milestone and royalty payments from commercial product sales, if any, from the products covered by the collaboration, as well as the potential of our technologies and product candidates; our updated strategic plans and the intended benefits thereof, our plans to seek strategic partnerships for our ophthalmology assets, and our financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this presentation. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted due to shortage and pressure on supply and logistics on the global market; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks; and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics

Overview

Focus on Axiomer®

Exclusively focused on the development of proprietary Axiomer® RNA editing platform across multiple therapeutic areas; initial focus on liver and CNS diseases

Novel mechanism of action, leading patent estate

Axiomer® was discovered in ProQR labs in 2014 and uses well-proven modality of oligonucleotides to recruit a novel mechanism of action

Validated across multiple genes

Preclinical data demonstrate Axiomer® is broadly validated across multiple genes

ADAR

Axiomer® is ADAR-mediated RNA editing, recruiting endogenous adenosine deaminase acting on RNA (ADAR)

Two pillars underly strategy

ProQR developing wholly owned pipeline with initial targets in liver-originated diseases

Selectively enter into partnerships: initial partnership with Lilly in September 2021, expansion announced December 2022

Cash-runway into mid-2026

Cash position of €128.6 M as of end of Q2 2023 provides runway to mid 2026, beyond multiple clinical data readouts

What is ADAR editing?

ADAR *(Adenosine Deaminase Acting on RNA)*



Enzyme that performs specific form of natural RNA editing, called **A-to-I editing.** During A-to-I editing an **A nucleotide (adenosine)** is changed into an **I nucleotide (inosine)**

Natural ADAR editing *(A-to-I)*



Axiomer® EONs unlock cellular machinery potential to treat diseases

By attracting ADARs and allowing highly specific editing

Natural ADAR editing *(A-to-I)*



Editing Oligonucleotide (EON)-directed therapeutic editing *(A-to-I)*



ADARs: Adenosine deaminases acting on RNA.

Driving the development of optimized EONs for therapeutic use

Sequence defines target
RNA binding and provides stability

EON total length
Between ~25 - 30 nt



ADAR-binding region (ABR)
Backbone modifications enable ADAR binding, and disable off-target editing

Optimized sequence and chemistry define functionality

- Increase editing efficacy
- Bring metabolic stability
- Prevent off-target ('bystander') editing
- Ensure bioavailability (cell and tissue uptake)
- Offer safety and tolerability at therapeutic doses

ADAR: Adenosine deaminase acting on RNA, EON: Editing oligonucleotide, Nt: nucleotides

Robust editing reported in the nervous system and liver

Cell models

>50% RNA editing of *ACTB* in human iPSC derived neurons



Up to 40% RNA editing of *ACTB* in human primary hepatocytes



Organoids

Up to 65% RNA editing of *APP* in cerebral organoids



Up to 40% RNA editing of *ACTB* in human LMTs



Mice *in vivo*

Up to 40% RNA editing in mice brain*
(leading to 26 fold protein change)



Up to 50% RNA editing of *ActB* in liver of mice



NHP *in vivo*

Up to 30% RNA editing in NHP brain*



Approx. 50% RNA editing in NHP spinal cord*



*Undisclosed target. Conditions of the *ACTB* iPSC derived neurons experiment: gymnosis, 2.5µM, single dose, n=3-4, 2 weeks, dPCR and conditions of ACTB editing experiment in human primary hepatocytes experiment: gymnosis, 10µM, single dose, N=6, 48 hours, dPCR. Conditions of the *APP* cerebral organoids of 150 days: gymnosis, 5µM, single dose, washout, n=5, 2 weeks, ddPCR, mean, SD. Conditions of the *ACTB* Liver microtissus (LMTs): gymnosis, 1µM, constant dose, 3 pools of 24 LMTs per condition, 14 days, dPCR, mean, SD. Conditions of the mice *in vivo* experiment: intracerebroventricular (ICV), 250µg, single dose, N=6, 4 weeks, editing: ddPCR and protein function: western blot, mean, SD and SEM. Condition of the *ActB* mice experiment: SC, 5 daily doses of 10 mg/kg, N=4, 1 week, ddPCR, mean, SD. Conditions of the non-human primate (NHP) in vivo experiment: intrathecal (IT), 12mg, single dose, n=3**, 7 days. ** Data of 2 NHPs not analyzable due to human error during injection procedure.

GalNAc increases RNA editing efficiency

BEA assay

GalNAc does not interfere A-to-I editing *in vitro*

*2nM target RNA, 6nM EON and 6nM ADAR2, N=1, BEA assay**



Mice *in vivo*

Mice treatment

In vivo



★ = *Dose of 4 x 10 mg/kg*

Analysis of mice liver

↓

Editing quantification using dPCR

10-fold change in editing in liver of mice**

SC, 4 doses of 10 mg/kg, N=4-5, 2weeks, dPCR, mean, SD



BEA, Biochemical editing assay; SC, subcutaneous; SD, standard deviation. *BEA assay timepoints 0, 0.5-, 1-, 2-, 5-, 10-, 25- and 50-min. **Undisclosed target.

Axiomer® creating a new class of medicines with broad therapeutic potential

Correction	Protein modulation		
			
Mutations correction Thousands of G-to-A mutations, many of them described in literature	**Alter protein function or include protective variants** Modified proteins achieving loss- or gain-of-functions that help addressing or preventing diseases	**Disrupt >400 different types of PTMs** Regulate protein activity, change localization, folding, preventing immune escape or slowing down degradation	**Change protein interactions** Changes localization, folding, protein function or prevents immune escape of glycosylated tumor antigens

BROAD THERAPEUTIC POTENTIAL

- Common diseases
- Rare diseases
- Target a wide variety of organs
- Treat so-far undruggable targets

PTMs: Post-translational modifications.

ProQR development pipeline

	TARGET	DISCOVERY	NON-CLINICAL	CLINICAL	GUIDANCE	ESTIMATED POPULATION
PROQR PROGRAMS						
CHOLESTATIC DISEASES	**AX-0810** *for* **NTCP**				Entry into clinical trials in late 2024 / early 2025	~ 100K[1]
CARDIOVASCULAR DISEASES	**AX-1412** *for* **B4GALT1**				Entry into clinical trials in late 2024 / early 2025	~ 200M[2]
	AX-1005 *for CVD*					
METABOLIC DISEASES	**AX-2911** *for NASH*					~ 16M
	AX-0601 *for obesity and T2D*					~ 650M
	AX-9115 *for rare metabolic condition*					~ 20K
RARE NEURO DISEASES	**AX-2402** *for neurodegenerative condition*					~ 30K
OTHERS	*Multiple targets in discovery pipeline*					
PARTNERED PROGRAMS						
Lilly	*Initial **5** undisclosed targets*	*Progress undisclosed*				
	*Next **5** undisclosed targets*	*Progress undisclosed*				
	*Up to **5** potential additional targets*					

[1]Approximately 100K people affected with Primary Sclerosing Cholangitis and Biliary Atresia in US and EU5. [2]Approximately 200 million people suffer from too high a level of cholesterol in US and EU5. *SLC10A1* is the gene that encodes for NTCP protein.
CVD: Cardiovascular Diseases, NASH: Nonalcoholic steatohepatitis, T2D: Type 2 Diabetes.
References: Boonstra K, Beuers U, Ponsioen CY. J Hepatol. 2012 May;56(5):1181-1188; Karlsen TH, et al. J Hepatol. 2017 Dec;67(6):1298-1323; Dyson JK, et al. Lancet. 2018 Jun 23;391(10139):2547-2559; Sundaram SS, et al. Liver Transpl. 2017 Jan;23(1):96-109. Raghu VK, et al. Liver Transpl. 2021 May;27(5):711-718; NORD, 2019. Tsao CW, et al. Circulation. 2022;145(8):e153–e639. World Health Organization, World Gastroenterology Organization

AX-0810 for cholestatic diseases

RNA-editing therapy for Primary Sclerosing Cholangitis and Congenital Biliary Atresia

Cholestatic diseases have high unmet medical need. Patients accumulate bile acid in liver leading to fibrosis and ultimately liver failure.

Initial indications are **Primary Sclerosing Cholangitis** affecting adults and Congenital **Biliary Atresia** affecting pediatrics early in life. Both conditions have no approved therapies and require liver transplantation.

Biliary Atresia is projected to affect ~24,000 pediatric individuals in US, EU and JP.
Primary Sclerosing Cholangitis is projected to affect more than 80,000 individuals in EU, US and JP.

AX-0810 is a unique therapeutic approach leading to a potentially disease modifying therapy by targeting the NTCP channel which is responsible for majority of bile acid re-uptake in liver cells.

AX-0810 is designed to reduce bile acids re-uptake into the liver

RNA editing to a loss of function variant of NTCP can improve liver function

AX-0810 therapy for cholestatic diseases



Reduced BA levels in the hepatocytes



- AX-0810 is a novel and "on target" approach reducing bile acid re-uptake into the hepatocytes
  - Transient and controlled approach introducing a loss of function of NTCP
- AX-0810 can reduce bile acid load in the liver
  - To alleviate associated pathology and symptoms in PSC and BA
  - To prevent or delay the development of cirrhosis, organ failure and need for transplant

BA: Bile acids, NTCP: Na-taurocholate cotransporting polypeptide, PSC: Primary Sclerosing Cholangitis. *SLC10A1* is the gene that encodes for NTCP protein.

Well-defined development path for AX-0810

PRECLINICAL STAGE	EARLY CLINICAL	LATE CLINICAL
Preclinical models available with strong translatability into the clinic	*Early insight on safety and target engagement using validated biomarkers*	*Clinical programs with disease specific endpoints for regulatory approval*
Translational models available • Organoids models • Animal models **Proof of mechanism measures in animal models** • Serum levels of ALP and γ-GT • Total bile acids in serum and liver • Hepatic inflammation and fibrosis	**Program with Phase 1 on healthy volunteers** **Validated biomarkers in cholestatic diseases** • Bile acids in serum, urine and feces • Liver enzymes • Serum cholesterol **Disease specific biomarkers in preparation for next trials:** • ALP for PSC • Bilirubin for BA	**Primary Sclerosing Cholangitis** Co-primary endpoint for regulatory approval: • Reduction in ALP and • Histological liver evaluation **Biliary atresia** • Time to liver transplantation • Mean change in total serum bilirubin levels, liver enzymes, bile acid levels, blood platelets and serum albumin

γ-GT: γ-glutamyl transferase; ALP, Alkaline phosphatase; BA, biliary atresia; BDL, Bile duct ligation; LMT, Liver microtissues; NTCP, Na-taurocholate cotransporting polypeptide; PSC, Primary Sclerosing Cholangitis

AX-1412 for cardiovascular diseases

RNA-editing therapy for cardiovascular disease (CVD)

Leading causes of death in the world

~18M people die from CVDs every year (32% of all global deaths). Despite therapies, the unmet medical need remains.

With projected increased number of patients

By 2035, >130 million adults in the US are projected to have some form of CVD with a total costs of $1.1 trillion

AX-1412 can become a stand-alone cardiovascular therapy that can also work synergistically with standard of care to further reduce risk of CVDs

AX-1412 introduces a protective variant that reduces multiple independent risk factors for CVDs as was found in human genetics research

AX-1412 brings a novel approach to reduce residual risk for a potential cardiovascular event

RNA editing to a loss of function variant of B4GALT1 can have pleiotropic effect targeting two CVD risk factors



***B4GALT1* p.N352S protective allele**

- Leads to hypo-galactosylation of apolipoprotein B100, fibrinogen

AX-1412 is a novel and unique approach to address CVD

- Pleiotropic effects for cardiovascular protection
- Not suitable for knockdown technologies, as leads to semi-lethality and severe development abnormalities in mouse studies

AX-1412 can lower LDL-C and fibrinogen levels to reduce residual risk in cardiovascular diseases

- Prevent or delay the development of cardiovascular events

ADAR: adenosine deaminase acting on RNA, ApoB: Apolipoprotein B, CVDs: cardiovascular diseases, LDL-C: Low-density lipoprotein cholesterol. Reference: Montasser ME. et al., 2021 Science 374(6572):1221-1227.

Well-defined development path for AX-1412

PRECLINICAL STAGE	EARLY CLINICAL	LATE CLINICAL
Preclinical models available with strong translatability into the clinic	*Early insight on safety and target engagement using validated biomarkers*	*Clinical programs with disease specific endpoints for regulatory approval*
Organoids models for CVD • Blood-derived myeloid cells and THP-1 cells • Cell-laden microtissue spheroids **Animal models** • The Apoe−/− mouse model **Proof of mechanism measures in animal models** • Serum lipid levels • Atherosclerotic lesion area • C-reactive protein (CRP) and Interleukin 6 (IL-6) • Endothelial function	**Programs with Phase 1 on healthy individuals** • Reduce potential signal-to-noise ratio as CVD patients have many comorbidities **General CVD biomarkers** • non-HDL-C • Triglycerides • Apoliprotein B **Target specific biomarkers** • LDL-C • Fibrinogen	**Primary endpoints** 1. All-cause mortality and fatal CVD events or 2. Composite endpoints (incl. fatal and non-fatal CVD events) **Secondary endpoints** • Could consider using biomarkers as surrogate endpoints to reasonably predict treatment effects on outcome.

Apoe: Apolipoprotein E, CVD: cardiovascular diseases, HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol, THP-1: human monocytic cell line

Value creation strategy

ProQR will develop its own pipeline and selectively enter into partnerships

ProQR Pipeline

- Build **in-house pipeline** based on Axiomer® RNA editing technology platform
- Initial focus on **liver originated diseases**

Partnerships

- Largely unencumbered platform, ProQR may **selectively enter partnerships**
- **Lilly partnership** with expansion announced December 2022 – total potential value of ~$3.9B

Multiple upcoming value-creating milestones

Platform

- Multiple platform updates over the next 12 months including NHP data in liver
- Plans to scale up discovery efforts ongoing
- Multiple scientific presentations and peer-reviewed publications in 2023 and 2024

Pipeline

- **AX-0810** for cholestatic diseases
  - Presentation of non-clinical proof of concept data over next 12 months
  - Update on translational data over the next 18 months to enable progression into CTA
  - Entry into clinical trials in late 2024 / early 2025
- **AX-1412** for CVD
  - Presentation of non-clinical proof of concept data over next 12 months
  - Update on translational data over the next 18 months to enable progression into CTA
  - Entry into clinical trials in late 2024 / early 2025

Partnerships and BD

- Eli Lilly $3.9 B partnership
  - Potential option exercise for expansion of deal to 15 targets, with $50 M opt-in payment to ProQR
  - Other milestone payments
- Potential additional multi-target discovery partnership
- ✓ Outlicensing of ophthalmology assets announced Aug 2023

Intellectual property

- Continued expansion of IP portfolio

Financial

- Cash position of €128.6 M as of end of Q2 2023 provides runway to mid 2026, beyond multiple clinical data readouts

Well positioned to advance Axiomer®

Science

- Deep understanding of basic science – ADAR, oligos
- Optimization of editing oligonucleotides (EONs) for therapeutic development

Axiomer® has broad applicability

- Large number of potential therapeutic applications
- *In vivo* POC established in nervous system, liver

Advancing toward the clinic

- Extensive translational and developmental expertise with oligo modality
- AX-0810 and AX-1412 initial pipeline targets

Leading IP position

- Axiomer® is protected by >10 published patent families
- Continuously investing in expanding IP estate

Strategic partnership strategy

- Lilly collaboration
- Selectively form additional partnerships
- Optionality and multiple value creating opportunities

Experienced leadership

- Deep RNA, corporate finance, and business development expertise across Management Team, Supervisory Board, and Scientific Advisory Board

Strong balance sheet

- Q2 2023 cash €128.6 M
- Cash runway to mid-2026, excluding potential for additional BD-related upside

ProQR®

IT'S IN OUR RNA

Resource slides

ProQR Leadership Team

Management Team

Daniel de Boer
Chief Executive Officer

Gerard Platenburg
Chief Scientific Officer

René Beukema
Chief Corporate Development Officer

Jurriaan Dekkers
Chief Financial Officer

Sheila Sponselee
VP, Head of People and Operations

Supervisory Board

Dinko Valerio
Chairman

James Shannon, MD

Alison Lawton

Bart Filius

Theresa Heggie

Begoña Carreño

John Maraganore, PhD
Strategic Advisor

In Memoriam

Henri Termeer
Honorary former board member

Scientific Advisory Board

James Shannon, MD
Chair

Art Levin, PhD

Phillip D. Zamore, PhD

Martin Maier, PhD

Peter A. Beal, PhD

Yi-Tao Yu, PhD

Leading IP supporting ADAR-mediated RNA editing platform technology

- Axiomer® IP strategy commenced in 2014 with first patent application filings
- Currently 11 published patent families, comprising 27 national/regional patents
- Axiomer® IP portfolio is constantly expanding
- Oppositions/appeals and several Third-Party Observations have been filed against a variety of applications and patents in the Axiomer® IP portfolio, all by strawmen

Overview of Axiomer® related patents

Docket	Priority	Feature	Status
1 (0004)	**17DEC2014**	**Targeted RNA Editing using endogenous ADARs**	Granted CA CN EP IL JP NZ RU ZA 2xUS
2 (0013)	**22JUN2016**	**Short EONs with wobble and/or mismatch base pairs**	Granted AU EA IL JP KR 2xUS
3 (0014)	**01SEP2016**	**Chemically modified short EONs**	Granted CN EP JP KR NZ ZA 2xUS
4 (0016)	19JAN2017	EONs + protecting SONs (heteroduplex formation)	Granted US
5 (0023)	18MAY2018	PS linkages / chiral linkages (*e.g.,* PS, PN)	Published
6 (0026)	11FEB2019	Phosphonacetate linkages / UNA modifications	Published
7 (0029)	03APR2019	MP linkages	Published
8 (0031)	24APR2019	Editing inhibition	Published
9 (0032)	13JUN2019	Benner's base (dZ)	Published Granted ZA
10 (0039)	23JUL2020	Split EONs	Published
11 (0045)	14FEB2022	PCSK9 editing	Published

In addition to the above, numerous patent applications are pending but have not yet been published.
ProQR expands its Axiomer® IP portfolio continuously.

ProQR Axiomer® IP

Broad coverage

- Axiomer® patent claims are broad and cover:
  - **Any type of chemically modified oligonucleotide** aimed at RNA editing of **any possible target** and **any possible disease** using **endogenous** ADAR
  - Specific targets
  - Oligonucleotides with chirally-controlled linkages
  - Oligonucleotides with all sorts of chemistries (also in the 'Central Triplet'), including **DNA**
- To note: claims directed to chemically modified oligonucleotides **do not cover viral delivery** of the oligonucleotide

Overview of key claims – 1

Granted claims in the 1st Axiomer® patent family relate to (chemically modified) oligonucleotides that comprise:

- **A targeting portion** for binding to a target RNA incl. target adenosine
- **A recruitment portion** (hairpin structure) for recruiting **endogenous** ADAR to edit the target adenosine



EP 3 234 134 B1 - Granted; appeal pending
US 10,676,737 - Granted
US 16/807,577 - Allowed

Claim 8. A method for making a change in a target RNA sequence in a human cell, comprising the steps of:

- introducing into the cell an oligonucleotide construct that is **sufficiently complementary** to bind by nucleobase pairing to the target RNA sequence, wherein the target RNA sequence comprises a target adenosine;
- allowing the formation of a double-stranded structure of the oligonucleotide construct with the target RNA sequence upon base pairing;
- allowing the double-stranded structure of the oligonucleotide and the target RNA sequence to recruit **an hADARl or hADAR2 enzyme naturally present in the cell;**
- allowing the hADARl or hADAR2 enzyme to perform deamination of the target adenosine to an inosine in the target RNA sequence.

Overview of key claims – 2

Granted claims in the 2nd Axiomer® patent family relate to oligonucleotides that do **not** have a hairpin structure, but instead have one or more wobbles and/or mismatches, and chemical modifications in the base, ribose sugar and/or linkage to increase stability and are still able to recruit **endogenous** ADAR to edit the target adenosine.



US 10,988,763 - Granted
US 11,649,454 - Granted

Target-specific claims:

- An AON capable of forming a double stranded complex with a target RNA in a cell, wherein: the target RNA encodes CFTR, CEP290**, alpha1- antitrypsin (A1AT)**, LRRK2, or BDNF, or the target RNA is encoded by the IDUA gene
- The AON is complementary to a target RNA region comprising a target adenosine
- The AON comprises one or more nucleotides with **one or more sugar modifications**
- The AON does **not** comprise a portion that is capable of forming an intramolecular stem-loop structure that is capable of binding an ADAR enzyme
- The AON is shorter than 100 nucleotides
- The AON **optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10** mismatches, wobbles and/or bulges with the complementary target RNA region, and, wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme **present in the cell**

Overview of key claims – 3

Granted claims in the 3rd Axiomer® patent family relate to oligonucleotides that do **not** have a hairpin structure, but have **chemical modifications** in the base, ribose sugar and/or linkage to increase stability and are still able to recruit **endogenous** ADAR to edit the target adenosine.



US 10,941,402 - Granted
US 17/152,982 - Allowed
EP 3 507 366 B1

An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell, said AON comprising **a Central Triplet** of 3 sequential nucleotides, wherein the nucleotide directly opposite the target adenosine is the middle nucleotide of the Central Triplet, wherein 1, 2 or 3 nucleotides in said Central Triplet comprise **a sugar modification and/or a base modification** to render the AON more stable and/or more effective in inducing deamination of the target adenosine; with the proviso that the middle nucleotide does not have a 2'-O-methyl modification.

ProQR Axiomer® IP

Summary

- ProQR's Axiomer® IP contains 3 early RNA editing platform patent families covering single-stranded oligonucleotides that recruit **endogenous** ADAR
- Oppositions/appeals and Third-Party Observations have been filed throughout these three patent families
- First (2014): oligonucleotides with a complementary (**targeting**) and a stem-loop (**recruiting**) portion
- Second (2016): oligonucleotides **without a stem-loop structure** but with **one or more mismatches** and chemical modifications
- Third (2016): oligonucleotides **without a stem-loop structure** but with specific chemical modifications in the '**Central Triplet**'

Agreement for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Programs

- Divestment of assets announced August 2023 – expected to close Q3 2023
- ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M in further development, regulatory and commercial payments, as well as additional royalties up to high teen percentage based on commercial sales in the US and EU
- Théa is an independent European pharmaceutical company specialized in the research, development, and commercialization of eye care products, based in Clermont-Ferrand, France
- Divestment supports ProQR's strategic focus on the Axiomer® RNA editing technology platform and continued advancement of pipeline programs, AX-0810 and AX-1412, focused on genetic diseases originating in the liver